Evolving Approaches in the Management of Neuroendocrine Tumor-Associated Carcinoid Syndrome

home / insights / evolving-approaches-in-the-management-of-neuroendocrine-tumor-associated-carcinoid-syndrome

Satya (Nanu) Das, MD, MSCI, Rodney Pommier, MD, and Jerome Zacks, MD, discuss how patients with neuroendocrine tumors progress to carcinoid syndrome and carcinoid heart disease, and how strategies for management have changed after key clinical trial data.

Funding provided by TerSera Therapeutics LLC. Content independently developed by OncLive.

EP. 1: Overview of Neuroendocrine Tumors (NETs)

Satya (Nanu) Das, MD, MSCI;Jerome Zacks, MD;Rodney Pommier, MD

September 13th 2022

Satya (Nanu) Das, MD, MSCI, provides an overview of the incidence rate and common symptoms of neuroendocrine tumors (NETs).

EP. 2: Overview of Carcinoid Syndrome (CS)

Satya (Nanu) Das, MD, MSCI;Jerome Zacks, MD;Rodney Pommier, MD

September 13th 2022

Rodney Pommier, MD, defines carcinoid syndrome and describes the process of diagnosis and clinical risk factors in patients.

EP. 3: Overview of Carcinoid Heart Disease (CHD)

Satya (Nanu) Das, MD, MSCI;Jerome Zacks, MD;Rodney Pommier, MD

September 20th 2022

Jerome Zacks, MD, explains carcinoid heart disease and its symptoms, and why it develops in some patients with NET-associated carcinoid syndrome.

EP. 4: Management of Carcinoid Syndrome-Related Symptoms

Satya (Nanu) Das, MD, MSCI;Jerome Zacks, MD;Rodney Pommier, MD

September 20th 2022

Dr Satya (Nanu) Das discusses the typical management strategies for carcinoid syndrome-related symptoms, highlighting the use of somatostatin analogs.

$Diagnosis and Management of Somatostatin Analog-Refractory Carcinoid Syndrome$

EP. 5: Diagnosis and Management of Somatostatin Analog-Refractory Carcinoid Syndrome

Satya (Nanu) Das, MD, MSCI;Jerome Zacks, MD;Rodney Pommier, MD

September 27th 2022

Dr Rodney Pommier gives an overview of somatostatin analog-refractory carcinoid syndrome and the recommended approaches for management in patients.

$Available Treatment Options for Somatostatin Analog-Refractory Carcinoid Syndrome$

EP. 6: Available Treatment Options for Somatostatin Analog-Refractory Carcinoid Syndrome

Satya (Nanu) Das, MD, MSCI;Jerome Zacks, MD;Rodney Pommier, MD

September 27th 2022

A medical oncologist reviews the currently available, NCCN-approved treatments for somatostatin analog-refractory carcinoid syndrome.

EP. 7: Data from the TELEPATH Trial and Real-World Analyses

Satya (Nanu) Das, MD, MSCI;Jerome Zacks, MD;Rodney Pommier, MD

October 4th 2022

Dr Pommier discusses key safety, efficacy, and quality of life data from the TELEPATH trial investigating the tryptophan hydroxylase inhibitor telotristat ethyl, while Dr Das comments on real-world data complements to the trial.

EP. 8: Prevention, Treatment, and Management of Carcinoid Heart Disease

Satya (Nanu) Das, MD, MSCI;Jerome Zacks, MD;Rodney Pommier, MD

October 4th 2022

Dr Jerome Zacks explains strategies to prevent, treat, and manage carcinoid heart disease, and emphasizes the need for multidisciplinary approaches.

EP. 9: Unmet Needs for Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome

Satya (Nanu) Das, MD, MSCI;Jerome Zacks, MD;Rodney Pommier, MD

October 11th 2022

Experts comment on the current unmet needs for patients with neuroendocrine tumor-associated carcinoid syndrome.

EP. 10: Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome

Satya (Nanu) Das, MD, MSCI;Jerome Zacks, MD;Rodney Pommier, MD

October 11th 2022

Drs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.